Delenex completes its management team
Thomas Jung becomes chief medical officer
A board certified dermatologist, Jung has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel, Switzerland.
In January 2008 he took leadership of the Ilaris development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.
Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.
Eric de La Fortelle, ceo of Delenex, said: ‘With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programmes to bring its major new compounds to clinical proof of concept.’
You may also like
Cell & Gene Therapy
iOrganBio launches with $2m seed round and unveils CellForge, the first AI-powered cell manufacturing platform
Founded by experts in stem cell biology, organoid systems and biomedical engineering, the company aims to revolutionise how human cells are designed and produced for drug discovery and regenerative medicine
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Pharma 5.0
Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption
Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster